Literature DB >> 9369430

Establishment and characterization of a new erythropoietin-dependent acute myeloid leukemia cell line, AS-E2.

Y Miyazaki1, K Kuriyama, M Higuchi, H Tsushima, H Sohda, N Imai, M Saito, T Kondo, M Tomonaga.   

Abstract

We have established an erythropoietin-dependent human leukemia cell line, AS-E2, from a patient with acute myeloid leukemia. These cells have many characteristics of late erythroid progenitor cells, they are positive for CD36, Glycophorin A, and CD71 but negative for CD41, and positive for benzidine and PAS staining. These cells express GATA-1 and have low affinity erythropoietin (EPO) receptor on their surface. Interestingly, AS-E2 cells are strictly dependent on EPO for their growth and survival; other cytokines including GM-CSF, stem cell factor, or IL-3 cannot support the growth of this cell line. These features are similar to late erythroid lineage cells, like normal BFU-E or CFU-E, and we have demonstrated that EPO stimulation induces the tyrosine phosphorylation of several proteins in AS-E2 cells including the EPO receptor and JAK2 kinase. This new cell line is a useful reagent to study biological and molecular events during the late stages of erythropoiesis, and to understand transforming events in human erythroid cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369430     DOI: 10.1038/sj.leu.2400838

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase.

Authors:  Ken Aizawa; Ryohei Kawasaki; Yoshihito Tashiro; Michinori Hirata; Koichi Endo; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2016-04-15       Impact factor: 2.490

2.  Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with low-dose prednisolone.

Authors:  Kazunari Aoki; Yuichiro Ono; Sumie Tabata; Akiko Matsushita; Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2013-01-26       Impact factor: 2.490

3.  Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor.

Authors:  Saghi Ghaffari; Zainab Jagani; Claire Kitidis; Harvey F Lodish; Roya Khosravi-Far
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

4.  Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus.

Authors:  Koji Hashimoto; Makoto Harada; Yuji Kamijo
Journal:  Int J Hematol       Date:  2016-06-23       Impact factor: 2.490

5.  Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.

Authors:  Leon A G J M van Aerts; Karen De Smet; Gabriele Reichmann; Jan Willem van der Laan; Christian K Schneider
Journal:  MAbs       Date:  2014       Impact factor: 5.857

6.  Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD.

Authors:  Akinori Hara; Kengo Furuichi; Akihiko Koshino; Haruka Yasuda; Trang Thi Thu Tran; Yasunori Iwata; Norihiko Sakai; Miho Shimizu; Shuichi Kaneko; Hiroyuki Nakamura; Takashi Wada
Journal:  Kidney Int Rep       Date:  2017-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.